血友病市場規模、佔有率和成長分析（按類型、產品、療法、治療和地區）- 產業預測（2025-2032 年）

2023 年血友病市場規模價值 135 億美元，預計將從 2024 年的 143.9 億美元成長到 2032 年的 240 億美元，預測期內（2025-2032 年）的複合年成長率為 6.6%。

受近期基因療法核准及一群前景看好的候選藥物的推動，血友病治療市場預計將出現強勁成長。人們對血友病的認知不斷提高，加上政府對新生兒早期檢測的舉措，進一步促進了市場的擴張。根據世界血友病聯盟統計，截至2021年10月，血友病主要影響男性，全球通報盛行率為209,614例，其中A型165,379例，B型33,076例，未知類型11,159例。高發病率刺激了可用治療方法的激增，並凸顯了該領域對有效治療方法和創新的迫切需求。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場進行機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

血友病市場規模（按類型和複合年成長率）（2025-2032）

• 市場概況
• A型血友病A
• B型血友病
• 血友病C
• 其他

血友病市場規模（依產品和複合年成長率） (2025-2032)

• 市場概況
• 血漿來源的凝血因子濃縮物
• 重組凝血因子濃縮物
• 去氨加壓素和抗纖溶藥物

血友病市場規模（依療法和複合年成長率） (2025-2032)

• 市場概況
• 一經請求
• 預防

血友病市場規模（依治療方式及複合年成長率） (2025-2032)

• 市場概況
• 替代療法
• ITI 治療
• 基因治療

血友病市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• 拜耳公司（德國）
• BioMarin製藥公司（美國）
• CSL Behring（澳洲）
• Kedrion（Italy）
• 諾和諾德（丹麥）
• 輝瑞公司（美國）
• 羅氏（中外製藥株式會社）（瑞士/日本）
• 賽諾菲（健贊公司）（法國／美國）
• 武田製藥（Shire Plc.）（日本/愛爾蘭）
• Grifols（西班牙）
• Octapharma（瑞士）
• F. Hoffmann-La Roche Ltd（瑞士）
• Biogen（美國）
• Baxalta（美國）
• LFB集團（法國）
• Bioverativ Inc.（美國）
• 生物產品實驗室有限公司（英國）
• Kogenate（德國）
• Sangamo Therapeutics, Inc.（美國）

結論和建議

Hemophilia Market size was valued at USD 13.5 billion in 2023 and is poised to grow from USD 14.39 billion in 2024 to USD 24.0 billion by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).

The hemophilia treatment market is poised for robust growth, spurred by recent gene therapy approvals and a pipeline of promising developmental candidates. Heightened awareness of hemophilia, alongside government initiatives for early neonatal detection, is further catalyzing market expansion. According to the World Federation of Hemophilia, as of October 2021, hemophilia predominantly affects males, with a reported global prevalence of 209,614 cases-165,379 of which are type A, 33,076 type B, and 11,159 of unknown type. The substantial prevalence rates are fueling increased adoption of available therapies, underscoring the urgent need for effective treatments and innovation within the sector, thereby positioning hemophilia management as a critical area of focus for healthcare providers and pharmaceutical companies alike.

Top-down and bottom-up approaches were used to estimate and validate the size of the Hemophilia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Hemophilia Market Segments Analysis

Global Hemophilia Market is segmented by Type, Product, Therapy, Treatment and Region. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, Hemophilia C and Others. Based on Product, the market is segmented into Plasma derived coagulation factor concentrates, Recombinant coagulation factor concentrates and Desmopressin and antifibrinolytic agents. Based on Therapy, the market is segmented into On-demand and Prophylaxis. Based on Treatment, the market is segmented into Replacement therapy, ITI therapy and Gene Therapy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Hemophilia Market

The hemophilia market is being driven by significant advancements in medical technology, particularly in gene therapy, recombinant factor concentrates, and personalized medicine. These innovations have revolutionized treatment strategies, offering patients improved therapeutic options that lead to better health outcomes and enhanced quality of life. As these cutting-edge therapies continue to evolve, they are not only transforming the management of hemophilia but also fostering a more tailored approach to treatment that resonates with individual patient needs. Consequently, the growing adoption of these advanced therapies is a key factor propelling the hemophilia market forward.

Restraints in the Hemophilia Market

The hemophilia market faces significant restraints primarily due to the high costs associated with treatment options, especially with the advent of novel therapies like gene therapy. These advancements, while promising, often come with hefty price tags that can create financial burdens for patients and healthcare systems alike. This economic barrier restricts access to cutting-edge treatments, which may hinder patient outcomes and overall disease management. Consequently, the financial implications of these innovative therapies remain a critical challenge within the hemophilia market, impacting the availability and accessibility of essential care for those affected by this bleeding disorder.

Market Trends of the Hemophilia Market

The hemophilia market is experiencing a significant shift towards gene therapy as a transformative treatment modality. This trend is driven by the increasing recognition of gene therapy's potential to address the root genetic causes of hemophilia, offering patients durable solutions that could replace the need for traditional factor replacement therapies. Advances in viral vector technologies and a deeper understanding of genetic engineering have catalyzed this shift, leading to numerous successful clinical trials that validate the efficacy and safety of gene therapies. As these innovations continue to unfold, they promise to enhance patient quality of life, reduce treatment frequency, and reshape the overall landscape of hemophilia care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemophilia Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hemophilia A
• Hemophilia B
• Hemophilia C
• Others

Global Hemophilia Market Size by Product & CAGR (2025-2032)

• Market Overview
• Plasma derived coagulation factor concentrates
• Recombinant coagulation factor concentrates
• Desmopressin and antifibrinolytic agents

Global Hemophilia Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• On-demand
• Prophylaxis

Global Hemophilia Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Replacement therapy
• ITI therapy
• Gene Therapy

Global Hemophilia Market Size & CAGR (2025-2032)

• North America (Type, Product, Therapy, Treatment)
  • US
  • Canada
• Europe (Type, Product, Therapy, Treatment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product, Therapy, Treatment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product, Therapy, Treatment)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product, Therapy, Treatment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (Genzyme Corporation) (France/United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Shire Plc.) (Japan/Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxalta (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioverativ Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kogenate (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations